Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family
Abstract Aims Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly charact...
Gespeichert in:
| Veröffentlicht in: | Europace (London, England) England), 2023-12, Vol.25 (12) |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 12 |
| container_start_page | |
| container_title | Europace (London, England) |
| container_volume | 25 |
| creator | Hayashi, Katsuhide Callahan, Thomas Rickard, John Younis, Arwa Baranowski, Bryan Martin, David Nakhla, Shady Tabaja, Chadi Wilkoff, Bruce L |
| description | Abstract
Aims
Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly characterized. We assessed the safety and efficacy of ICD TLE and the impact of manufacturer ICD model family on the outcomes.
Methods and results
The study cohort included all consecutive patients with ICD who underwent TLE between 2013 and 2022 and are enrolled in the Cleveland Clinic Prospective TLE Registry. A total of 885 ICD leads (median implant duration 8 years) in 810 patients were included. Complete ICD TLE success was achieved in 97.2% of the leads (n = 860) and in 98.0% of the patients (n = 794). Major complications occurred in 22 patients (2.7%). Complete procedural success rate varied by manufacturer and lead family; Medtronic 98.9%, Abbott 95.9%, Boston Scientific 95.0%, Biotronik 91.2%, P = 0.03, and Linox family leads had the lowest, 89.7% P = 0.02. Multivariable predictors of incomplete ICD lead removal included ICD lead age > 10 years and Linox family lead. Multivariable predictors of major complications included ICD lead age > 15 years and longer lead extraction time, and predictors of all-cause mortality within 30 days included lead extraction for infection, end-stage renal disease, and higher New York Heart Association functional class.
Conclusion
Complete and safe ICD lead removal rate by TLE is extremely high but varied by manufacturer and lead family. Linox family lead and >10 years lead age were independent predictors of incomplete lead removal.
Graphical Abstract
Graphical Abstract
ICD transvenous lead extraction outcomes by lead family. *Major complication is expressed by cases. Categorical data are presented as number (percentage). ICD, implantable cardioverter-defibrillator; HV, high voltage; LV, low voltage; PTFE, polytetrafluoroethylene insulation. Procedural success rate by transvenous lead extraction varied by lead family, P < 0.0001. |
| doi_str_mv | 10.1093/europace/euad345 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10751850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/europace/euad345</oup_id><sourcerecordid>2893844829</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-24862256aa07090f6fc2e97b0936671fbd11061283ace361fe428972e05194ad3</originalsourceid><addsrcrecordid>eNqFUclKBTEQDKLoc7l7khwFGc0yW04i4gYPvOg5ZDIdjWQmYzLz8P29kbegJ09d0NXVXV0InVJySYngVzAFPygNCaiW58UOmtGCs4wRwXYTJkJkBWXiAB3G-EEIqZgo9tEBrxOuBZ8he_c1BqVH63vsp1H7DiL2BttucKofVeMAaxVa6xcQRghZC8Y2wTqnRh-wA9VGvFBhiZsl7lQ_mSQ2BQhY9S3ufAsOG9VZtzxGe0a5CCfreoRe7-9ebh-z-fPD0-3NPNM552PG8rpkrCiVIhURxJRGMxBVk-yWZUVN01JKSspqnnzzkhrIWS0qBqSgIk9fOELXK91hajpoNfTJoJNDsF06U3pl5d9Ob9_lm19ISqqC1gVJCudrheA_J4ij7GzUkCz34Kco0z5e53nNRKKSFVUHH2MAs91DifyJSG4ikuuI0sjZ7_u2A5tMEuFiRfDT8L_cNx-LofQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2893844829</pqid></control><display><type>article</type><title>Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family</title><source>MEDLINE</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Hayashi, Katsuhide ; Callahan, Thomas ; Rickard, John ; Younis, Arwa ; Baranowski, Bryan ; Martin, David ; Nakhla, Shady ; Tabaja, Chadi ; Wilkoff, Bruce L</creator><creatorcontrib>Hayashi, Katsuhide ; Callahan, Thomas ; Rickard, John ; Younis, Arwa ; Baranowski, Bryan ; Martin, David ; Nakhla, Shady ; Tabaja, Chadi ; Wilkoff, Bruce L</creatorcontrib><description>Abstract
Aims
Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly characterized. We assessed the safety and efficacy of ICD TLE and the impact of manufacturer ICD model family on the outcomes.
Methods and results
The study cohort included all consecutive patients with ICD who underwent TLE between 2013 and 2022 and are enrolled in the Cleveland Clinic Prospective TLE Registry. A total of 885 ICD leads (median implant duration 8 years) in 810 patients were included. Complete ICD TLE success was achieved in 97.2% of the leads (n = 860) and in 98.0% of the patients (n = 794). Major complications occurred in 22 patients (2.7%). Complete procedural success rate varied by manufacturer and lead family; Medtronic 98.9%, Abbott 95.9%, Boston Scientific 95.0%, Biotronik 91.2%, P = 0.03, and Linox family leads had the lowest, 89.7% P = 0.02. Multivariable predictors of incomplete ICD lead removal included ICD lead age > 10 years and Linox family lead. Multivariable predictors of major complications included ICD lead age > 15 years and longer lead extraction time, and predictors of all-cause mortality within 30 days included lead extraction for infection, end-stage renal disease, and higher New York Heart Association functional class.
Conclusion
Complete and safe ICD lead removal rate by TLE is extremely high but varied by manufacturer and lead family. Linox family lead and >10 years lead age were independent predictors of incomplete lead removal.
Graphical Abstract
Graphical Abstract
ICD transvenous lead extraction outcomes by lead family. *Major complication is expressed by cases. Categorical data are presented as number (percentage). ICD, implantable cardioverter-defibrillator; HV, high voltage; LV, low voltage; PTFE, polytetrafluoroethylene insulation. Procedural success rate by transvenous lead extraction varied by lead family, P < 0.0001.</description><identifier>ISSN: 1099-5129</identifier><identifier>EISSN: 1532-2092</identifier><identifier>DOI: 10.1093/europace/euad345</identifier><identifier>PMID: 38000893</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adolescent ; Child ; Clinical Research ; Defibrillators, Implantable - adverse effects ; Device Removal - adverse effects ; Device Removal - methods ; Humans ; Pacemaker, Artificial ; Prospective Studies ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Europace (London, England), 2023-12, Vol.25 (12)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-24862256aa07090f6fc2e97b0936671fbd11061283ace361fe428972e05194ad3</citedby><cites>FETCH-LOGICAL-c433t-24862256aa07090f6fc2e97b0936671fbd11061283ace361fe428972e05194ad3</cites><orcidid>0000-0001-7269-9808 ; 0000-0001-5281-7598 ; 0000-0002-2485-5025 ; 0000-0001-8905-9233 ; 0000-0002-4495-3845</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751850/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751850/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1604,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38000893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hayashi, Katsuhide</creatorcontrib><creatorcontrib>Callahan, Thomas</creatorcontrib><creatorcontrib>Rickard, John</creatorcontrib><creatorcontrib>Younis, Arwa</creatorcontrib><creatorcontrib>Baranowski, Bryan</creatorcontrib><creatorcontrib>Martin, David</creatorcontrib><creatorcontrib>Nakhla, Shady</creatorcontrib><creatorcontrib>Tabaja, Chadi</creatorcontrib><creatorcontrib>Wilkoff, Bruce L</creatorcontrib><title>Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family</title><title>Europace (London, England)</title><addtitle>Europace</addtitle><description>Abstract
Aims
Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly characterized. We assessed the safety and efficacy of ICD TLE and the impact of manufacturer ICD model family on the outcomes.
Methods and results
The study cohort included all consecutive patients with ICD who underwent TLE between 2013 and 2022 and are enrolled in the Cleveland Clinic Prospective TLE Registry. A total of 885 ICD leads (median implant duration 8 years) in 810 patients were included. Complete ICD TLE success was achieved in 97.2% of the leads (n = 860) and in 98.0% of the patients (n = 794). Major complications occurred in 22 patients (2.7%). Complete procedural success rate varied by manufacturer and lead family; Medtronic 98.9%, Abbott 95.9%, Boston Scientific 95.0%, Biotronik 91.2%, P = 0.03, and Linox family leads had the lowest, 89.7% P = 0.02. Multivariable predictors of incomplete ICD lead removal included ICD lead age > 10 years and Linox family lead. Multivariable predictors of major complications included ICD lead age > 15 years and longer lead extraction time, and predictors of all-cause mortality within 30 days included lead extraction for infection, end-stage renal disease, and higher New York Heart Association functional class.
Conclusion
Complete and safe ICD lead removal rate by TLE is extremely high but varied by manufacturer and lead family. Linox family lead and >10 years lead age were independent predictors of incomplete lead removal.
Graphical Abstract
Graphical Abstract
ICD transvenous lead extraction outcomes by lead family. *Major complication is expressed by cases. Categorical data are presented as number (percentage). ICD, implantable cardioverter-defibrillator; HV, high voltage; LV, low voltage; PTFE, polytetrafluoroethylene insulation. Procedural success rate by transvenous lead extraction varied by lead family, P < 0.0001.</description><subject>Adolescent</subject><subject>Child</subject><subject>Clinical Research</subject><subject>Defibrillators, Implantable - adverse effects</subject><subject>Device Removal - adverse effects</subject><subject>Device Removal - methods</subject><subject>Humans</subject><subject>Pacemaker, Artificial</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1099-5129</issn><issn>1532-2092</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFUclKBTEQDKLoc7l7khwFGc0yW04i4gYPvOg5ZDIdjWQmYzLz8P29kbegJ09d0NXVXV0InVJySYngVzAFPygNCaiW58UOmtGCs4wRwXYTJkJkBWXiAB3G-EEIqZgo9tEBrxOuBZ8he_c1BqVH63vsp1H7DiL2BttucKofVeMAaxVa6xcQRghZC8Y2wTqnRh-wA9VGvFBhiZsl7lQ_mSQ2BQhY9S3ufAsOG9VZtzxGe0a5CCfreoRe7-9ebh-z-fPD0-3NPNM552PG8rpkrCiVIhURxJRGMxBVk-yWZUVN01JKSspqnnzzkhrIWS0qBqSgIk9fOELXK91hajpoNfTJoJNDsF06U3pl5d9Ob9_lm19ISqqC1gVJCudrheA_J4ij7GzUkCz34Kco0z5e53nNRKKSFVUHH2MAs91DifyJSG4ikuuI0sjZ7_u2A5tMEuFiRfDT8L_cNx-LofQ</recordid><startdate>20231206</startdate><enddate>20231206</enddate><creator>Hayashi, Katsuhide</creator><creator>Callahan, Thomas</creator><creator>Rickard, John</creator><creator>Younis, Arwa</creator><creator>Baranowski, Bryan</creator><creator>Martin, David</creator><creator>Nakhla, Shady</creator><creator>Tabaja, Chadi</creator><creator>Wilkoff, Bruce L</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7269-9808</orcidid><orcidid>https://orcid.org/0000-0001-5281-7598</orcidid><orcidid>https://orcid.org/0000-0002-2485-5025</orcidid><orcidid>https://orcid.org/0000-0001-8905-9233</orcidid><orcidid>https://orcid.org/0000-0002-4495-3845</orcidid></search><sort><creationdate>20231206</creationdate><title>Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family</title><author>Hayashi, Katsuhide ; Callahan, Thomas ; Rickard, John ; Younis, Arwa ; Baranowski, Bryan ; Martin, David ; Nakhla, Shady ; Tabaja, Chadi ; Wilkoff, Bruce L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-24862256aa07090f6fc2e97b0936671fbd11061283ace361fe428972e05194ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescent</topic><topic>Child</topic><topic>Clinical Research</topic><topic>Defibrillators, Implantable - adverse effects</topic><topic>Device Removal - adverse effects</topic><topic>Device Removal - methods</topic><topic>Humans</topic><topic>Pacemaker, Artificial</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hayashi, Katsuhide</creatorcontrib><creatorcontrib>Callahan, Thomas</creatorcontrib><creatorcontrib>Rickard, John</creatorcontrib><creatorcontrib>Younis, Arwa</creatorcontrib><creatorcontrib>Baranowski, Bryan</creatorcontrib><creatorcontrib>Martin, David</creatorcontrib><creatorcontrib>Nakhla, Shady</creatorcontrib><creatorcontrib>Tabaja, Chadi</creatorcontrib><creatorcontrib>Wilkoff, Bruce L</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Europace (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hayashi, Katsuhide</au><au>Callahan, Thomas</au><au>Rickard, John</au><au>Younis, Arwa</au><au>Baranowski, Bryan</au><au>Martin, David</au><au>Nakhla, Shady</au><au>Tabaja, Chadi</au><au>Wilkoff, Bruce L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family</atitle><jtitle>Europace (London, England)</jtitle><addtitle>Europace</addtitle><date>2023-12-06</date><risdate>2023</risdate><volume>25</volume><issue>12</issue><issn>1099-5129</issn><eissn>1532-2092</eissn><abstract>Abstract
Aims
Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly characterized. We assessed the safety and efficacy of ICD TLE and the impact of manufacturer ICD model family on the outcomes.
Methods and results
The study cohort included all consecutive patients with ICD who underwent TLE between 2013 and 2022 and are enrolled in the Cleveland Clinic Prospective TLE Registry. A total of 885 ICD leads (median implant duration 8 years) in 810 patients were included. Complete ICD TLE success was achieved in 97.2% of the leads (n = 860) and in 98.0% of the patients (n = 794). Major complications occurred in 22 patients (2.7%). Complete procedural success rate varied by manufacturer and lead family; Medtronic 98.9%, Abbott 95.9%, Boston Scientific 95.0%, Biotronik 91.2%, P = 0.03, and Linox family leads had the lowest, 89.7% P = 0.02. Multivariable predictors of incomplete ICD lead removal included ICD lead age > 10 years and Linox family lead. Multivariable predictors of major complications included ICD lead age > 15 years and longer lead extraction time, and predictors of all-cause mortality within 30 days included lead extraction for infection, end-stage renal disease, and higher New York Heart Association functional class.
Conclusion
Complete and safe ICD lead removal rate by TLE is extremely high but varied by manufacturer and lead family. Linox family lead and >10 years lead age were independent predictors of incomplete lead removal.
Graphical Abstract
Graphical Abstract
ICD transvenous lead extraction outcomes by lead family. *Major complication is expressed by cases. Categorical data are presented as number (percentage). ICD, implantable cardioverter-defibrillator; HV, high voltage; LV, low voltage; PTFE, polytetrafluoroethylene insulation. Procedural success rate by transvenous lead extraction varied by lead family, P < 0.0001.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>38000893</pmid><doi>10.1093/europace/euad345</doi><orcidid>https://orcid.org/0000-0001-7269-9808</orcidid><orcidid>https://orcid.org/0000-0001-5281-7598</orcidid><orcidid>https://orcid.org/0000-0002-2485-5025</orcidid><orcidid>https://orcid.org/0000-0001-8905-9233</orcidid><orcidid>https://orcid.org/0000-0002-4495-3845</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1099-5129 |
| ispartof | Europace (London, England), 2023-12, Vol.25 (12) |
| issn | 1099-5129 1532-2092 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10751850 |
| source | MEDLINE; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Child Clinical Research Defibrillators, Implantable - adverse effects Device Removal - adverse effects Device Removal - methods Humans Pacemaker, Artificial Prospective Studies Retrospective Studies Treatment Outcome |
| title | Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A27%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extraction%20outcomes%20of%20implantable%20cardioverter-defibrillator%20leads%20vary%20by%20manufacturer%20and%20model%20family&rft.jtitle=Europace%20(London,%20England)&rft.au=Hayashi,%20Katsuhide&rft.date=2023-12-06&rft.volume=25&rft.issue=12&rft.issn=1099-5129&rft.eissn=1532-2092&rft_id=info:doi/10.1093/europace/euad345&rft_dat=%3Cproquest_pubme%3E2893844829%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2893844829&rft_id=info:pmid/38000893&rft_oup_id=10.1093/europace/euad345&rfr_iscdi=true |